Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Department of Physiology, Hallym University College of Medicine, Chuncheon, Republic of Korea.
Mol Psychiatry. 2021 Dec;26(12):7838-7850. doi: 10.1038/s41380-021-01284-x. Epub 2021 Sep 6.
Respiratory chain complex I deficiency elicits mitochondrial dysfunction and reactive oxidative species (ROS), which plays a crucial role in Parkinson's disease (PD) pathogenesis. However, it remains unclear whether the impairment in other complexes in the mitochondrial oxidative phosphorylation chain is also sufficient to trigger PD onset. Here we show that inhibition of Complex II or III in the electron transport chain (ETC) induces the motor disorder and PD pathologies in neuronal Thy1-C/EBPβ transgenic mice. Through a cell-based screening of mitochondrial respiratory chain inhibitors, we identified TTFA (complex II inhibitor) and Atovaquone (complex III inhibitor), which robustly block the oxidative phosphorylation functions, strongly escalate ROS, and activate C/EBPβ/AEP pathway that triggers dopaminergic neuronal cell death. Oral administration of these inhibitors to Thy1-C/EBPβ mice elicits constipation and motor defects, associated with Lewy body-like inclusions. Deletion of SDHD (Succinate dehydrogenase) gene from the complex II in the Substantia Nigra of Thy1-C/EBPβ mice triggers ROS and PD pathologies, resulting in motor disorders. Hence, our findings demonstrate that mitochondrial ETC inactivation triggers PD pathogenesis via activating C/EBPβ/AEP pathway.
呼吸链复合物 I 缺陷会引起线粒体功能障碍和活性氧(ROS),这在帕金森病(PD)发病机制中起着关键作用。然而,其他线粒体氧化磷酸化链中的复合物的损伤是否足以引发 PD 的发生尚不清楚。在这里,我们表明电子传递链(ETC)中复合物 II 或 III 的抑制会诱导神经元 Thy1-C/EBPβ转基因小鼠的运动障碍和 PD 病理。通过对线粒体呼吸链抑制剂的基于细胞的筛选,我们鉴定出 TTFA(复合物 II 抑制剂)和阿托伐醌(复合物 III 抑制剂),它们可强烈抑制氧化磷酸化功能,强烈增加 ROS,并激活 C/EBPβ/AEP 途径,从而引发多巴胺能神经元细胞死亡。这些抑制剂的口服给予 Thy1-C/EBPβ 小鼠会引起便秘和运动缺陷,伴有路易体样包涵体。从 Thy1-C/EBPβ 小鼠的黑质中的复合物 II 中删除 SDHD(琥珀酸脱氢酶)基因会引发 ROS 和 PD 病理,导致运动障碍。因此,我们的研究结果表明,线粒体 ETC 失活通过激活 C/EBPβ/AEP 途径引发 PD 发病机制。